LOS ANGELES -- (Business Wire)
Lundin Law PC announces a class action lawsuit has been filed against
Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (FOLD)
concerning possible violations of federal securities laws between
September 15, 2015 and October 1, 2015. Investors who purchased or
otherwise acquired shares during the Class Period should contact the
Firm in advance of the December 7, 2015, lead plaintiff motion deadline.
To participate in this class action lawsuit, please contact Brian
Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.
According to the complaint, on October 2, 2015, Amicus announced that
after meeting with FDA officials, the Company does not anticipate being
able to submit a new drug application (NDA) for migalastat, the
company's Fabry disease treatment, by the end of the year. When the
truth was revealed, shares dropped, harming investors.
No class has been certified in the above action. Until a class is
certified, you are not considered represented by an attorney. You may
also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based
in Los Angeles.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005540/en/
Contacts:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlaw.com
Source: Lundin Law PC
© 2024 Canjex Publishing Ltd. All rights reserved.